Thermo Fisher Scientific Inc. $TMO Shares Sold by Northeast Investment Management

Northeast Investment Management decreased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.4% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 81,692 shares of the medical research company’s stock after selling 1,143 shares during the quarter. Thermo Fisher Scientific accounts for about 1.7% of Northeast Investment Management’s investment portfolio, making the stock its 19th largest position. Northeast Investment Management’s holdings in Thermo Fisher Scientific were worth $40,154,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of TMO. High Note Wealth LLC raised its holdings in Thermo Fisher Scientific by 170.6% during the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after buying an additional 29 shares during the period. JPL Wealth Management LLC purchased a new position in shares of Thermo Fisher Scientific in the third quarter worth approximately $28,000. Swiss RE Ltd. acquired a new position in Thermo Fisher Scientific in the 4th quarter worth approximately $28,000. Beacon Financial Strategies CORP purchased a new position in Thermo Fisher Scientific during the 4th quarter worth approximately $29,000. Finally, Olistico Wealth LLC acquired a new stake in Thermo Fisher Scientific during the 4th quarter valued at $29,000. 89.23% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

TMO has been the subject of several recent analyst reports. Royal Bank Of Canada set a $490.00 target price on Thermo Fisher Scientific and gave the stock a “sector perform” rating in a research report on Thursday, May 14th. Robert W. Baird decreased their price objective on Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. Jefferies Financial Group upgraded Thermo Fisher Scientific to a “strong-buy” rating in a report on Friday, April 24th. Stifel Nicolaus decreased their price target on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating for the company in a report on Friday, April 24th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Wednesday, April 8th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $608.95.

Thermo Fisher Scientific News Summary

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Thermo Fisher is showcasing new AI-enabled, end-to-end biopharma tools at the BIO International Convention, including Orbitrap mass spectrometry upgrades, AI software, and integrated lab solutions, reinforcing its position as a full-service partner in drug development. Is Thermo Fisher (TMO) Quietly Redefining Its Edge With AI-Enabled, End-to-End Biopharma Tools?
• Positive Sentiment: Recent commentary highlighted support from Thermo Fisher’s long-range growth targets, Clario acquisition integration, and fresh analyst optimism, all of which can help lift the stock when investors are looking for visibility and execution upside. Thermo Fisher gains as investors weigh growth targets, Clario integration, and fresh analyst support
• Neutral Sentiment: Multiple industry pieces continued to position Thermo Fisher as a key player in fast-growing life sciences and lab services markets, which supports the broader investment thesis but is not a direct near-term catalyst. Global Laboratory Equipment Services Market Size/Share Worth USD 62.83 Billion by 2035
• Neutral Sentiment: Thermo Fisher’s Q1 earnings comparison article does not point to a new operational surprise, but it reinforces that the company has been delivering solid results relative to peers. Q1 Earnings Highlights: Thermo Fisher (NYSE:TMO) Vs The Rest Of The Research Tools & Consumables Stocks

Insider Buying and Selling at Thermo Fisher Scientific

In other news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the transaction, the chief operating officer owned 25,051 shares in the company, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO opened at $506.19 on Friday. Thermo Fisher Scientific Inc. has a one year low of $401.45 and a one year high of $643.99. The business’s 50-day moving average price is $474.44 and its two-hundred day moving average price is $520.23. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15. The company has a market capitalization of $188.11 billion, a P/E ratio of 27.83, a price-to-earnings-growth ratio of 2.18 and a beta of 0.88.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The business had revenue of $11.01 billion during the quarter, compared to analyst estimates of $10.86 billion. During the same period in the previous year, the company earned $5.15 EPS. The firm’s revenue was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Analysts anticipate that Thermo Fisher Scientific Inc. will post 24.85 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Monday, June 15th will be given a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend is Monday, June 15th. Thermo Fisher Scientific’s payout ratio is currently 10.34%.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.